To build upon the success of our COBRE program and the achievements that our COBRE investigator's made in Phase I and II, in Phase III we will implement the Pilot Project grant program as a means to support innovative research studies in the area of cardiovascular biology. The objective of this program is to provide funds to allow investigators collect adequate preliminary data for submission of highly competitive NIH R01 or equivalent extramural grant applications. It is expected that the program will also expand the scope of the current Cardiovascular Center research efforts in cardiovascular biology, including identifying new approaches to treat cardiovascular disease. In order to accomplish these objectives, the Phase Ml COBRE will support meritorious Pilot Projects that fall under two categories;1) Junior Investigator grants, and 2) New Project grants. The total direct costs allowed for each project will be $50,000 per year for a maximum of two years pending demonstration of satisfactory progress. Project areas of particular interest to be funded include, but are not limited to, investigations that will expand the Center's thematic focus in fundamental vascular and cardiac biology, cardiac and kidney ischemia and reperfusion injury, neurohumoral control of blood pressure and kidney function, and cardiopulmonary patho-physiology. Following internal review, the project selection process is based on an NIH style review conducted by the members ofthe External Advisory Committee. As established in Phase I and Phase 11, our COBER Mentors will play a pivotal role in guiding the scientific and career development of new Junior Investigators. The Pilot Project program will provide opportunities to purse new avenues of cardiovascular research while stimulating use of COBRE Core Facilities. Together, this will facilitate expansion of our Cardiovascular Center, which will help to recruit new investigators to our program and retain the most talented and qualified investigators in our area.
High blood pressure, high LDL cholesterol, diabetes, and smoking are key risk factors for heart disease, which is the leading cause of death (~ 600,000 per year) for people of most ethnicities in the United States. The Pilot Project grant program will build upon the structure and success of our COBRE program by funding highly promising pilot research projects that will expand our Center's scope of research in cardiovascular hioloav and disease.
|Washington, Shannan D; Edenfield, Samantha I; Lieux, Caroline et al. (2018) Depletion of the insulator protein CTCF results in HSV-1 reactivation in vivo. J Virol :|
|Lammi, Matthew R; Saketkoo, Lesley Ann; Gordon, Jessica K et al. (2018) Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort. Pulm Circ 8:2045893218757404|
|Simon, Liz; Siggins, Robert; Winsauer, Peter et al. (2018) Simian Immunodeficiency Virus Infection Increases Blood Ethanol Concentration Duration After Both Acute and Chronic Administration. AIDS Res Hum Retroviruses 34:178-184|
|Trivedi, Rishi K; Polhemus, David J; Li, Zhen et al. (2018) Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. J Am Heart Assoc 7:|
|Tsumagari, Koji; Abd Elmageed, Zakaria Y; Sholl, Andrew B et al. (2018) Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. Endocr Relat Cancer 25:99-109|
|Ghonim, Mohamed A; Wang, Jeffrey; Ibba, Salome V et al. (2018) Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway. J Transl Med 16:243|
|Connick, J Patrick; Reed, James R; Backes, Wayne L (2018) Characterization of Interactions Among CYP1A2, CYP2B4, and NADPH-cytochrome P450 Reductase: Identification of Specific Protein Complexes. Drug Metab Dispos 46:197-203|
|Lassak, Adam; Dean, Mathew; Wyczechowska, Dorota et al. (2018) Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival. Mol Cell Biol 38:|
|Carvalho-Galvão, Alynne; Ogunlade, Blessing; Xu, Jiaxi et al. (2018) Central administration of TRV027 improves baroreflex sensitivity and vascular reactivity in spontaneously hypertensive rats. Clin Sci (Lond) 132:1513-1527|
|Berger, Nathan A; Besson, Valerie C; Boulares, A Hamid et al. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175:192-222|
Showing the most recent 10 out of 64 publications